Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
32,079,500
-
Share change
-
+3,191,554
-
Total reported value
-
$33,361,056
-
Price per share
-
$1.04
-
Number of holders
-
65
-
Value change
-
+$3,161,589
-
Number of buys
-
25
-
Number of sells
-
34
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2020
As of 31 Mar 2020,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,079,500 shares.
The largest 10 holders included
MFN Partners Management, LP, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Endurant Capital Management LP, Samsara BioCapital, LLC, EcoR1 Capital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Sofinnova Investments, Inc., Vivo Capital, LLC, and Rock Springs Capital Management LP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.